Skip to main content

Table 2 Genomic subgroups of canonical and non-canonical B-ALL alterations in study patients

From: Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

  Genomic alterations Pediatric group (n = 122) Adult group (n = 38) Total cohort (n = 160) p-Value (Chi-Square)
Canonical alterations t(12;21)/ETV6-RUNX1 33 (27.1%) 1 (2.6%) 34 (21.3%) < 0.001
t(1;19)/TCF3-PBX1 7 (5.7%) 3 (7.9%) 10 (6.3%) 0.701
11q23/KMT2A gene rearrangements 4 (3.3%) 7 (18.4%) 11 (6.9%) 0.004
iAMP21 3 (2.5%) 0 3 (1.9%) 0.331
dic(9;20) 0 1 (2.6%) 1 (0.6%) 0.071
High hyperdiploidy 32 (26.2%) 3 (7.9%) 35 (21.9%) 0.030
Low hypodiploidy 2 (1.6%) 3 (7.9%) 5 (3.1%) 0.086
No canonical alterations 41 (33.6%) 20 (52.7%) 61 (38.1%)  
Non-canonical alterations   n = 75 n = 26 n = 101  
ABL-class fusions 0 3 (11.5%) 3 (3%) 0.003
JAK-STAT pathway fusions 2 (2.7%) 2 (7.7%) 4 (4%) 0.262
Other fusionsa 10 (13.3%) 0 10 (9.9%) 0.050
JAK-STAT pathway mutations 6 (8%) 4 (15.4%) 10 (9.9%) 0.182
Ras pathway mutations 39 (52%) 14 (53.8%) 53 (52.5%) 0.772
FLT3-TKD mutations 7 (9.3%) 1 (3.8%) 8 (7.9%) 0.378
  1. aPAX5-NCOA5, PAX5-ETV6, PAX5-FOXP1, PAX5-NOL4L, PAX5-GREB1L, EP300-ZNF384, TCF3-ZNF384, ETV6-RUNX2, CUX1-NUTM1